Aug 13, 2020
Palatin Technologies Participates In Canaccord Genuity's 40th Annual Growth Conference
Feb 19, 2020
Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643
Feb 11, 2020
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights
Feb 06, 2020
Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on February 11, 2020
Nov 13, 2019
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2020 Results and Provides Corporate Update
Nov 07, 2019
Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on November 13, 2019
Oct 16, 2019
Vyleesi(TM) Phase 3 Data To Be Presented At The 13th European Society Of Gynecology Congress
Sep 12, 2019
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2019 Results
Sep 11, 2019
Palatin Technologies, Inc. to Report Fourth Quarter & Fiscal Year End 2019 Results; Teleconference and Webcast to be held on September 12, 2019
Sep 09, 2019
Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market to 2027: Affordable Reimbursement Scenario for Pharmacotherapy Employed in the Treatment of HSDD
Aug 29, 2019
BioPlus Specialty Pharmacy in Semi-Exclusive Relationship to Dispense Vyleesi(TM) (Bremelanotide Injection)
Aug 06, 2019
Palatin Technologies To Present At Canaccord Genuity's 39th Annual Growth Conference
Jul 01, 2019
Palatin Technologies Provides Mid-Calendar Year Corporate Update
Jun 21, 2019
FDA Approves New Drug Application for Vyleesi(TM) (bremelanotide injection)
May 16, 2019
Lannett Begins Marketing Generic Adderall®
May 09, 2019
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on May 9, 2019
May 03, 2019
Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on May 9, 2019
Apr 12, 2019
The Food and Drug Administration (FDA) Determines that Women Taking Addyi May Safely Consume Alcohol
Apr 04, 2019
Palatin Technologies Announces Positive Top Line Results of Oral Clinical Study of PL-8177 for Ulcerative Colitis and Other Inflammatory Bowel Diseases
Aug 18, 2017
Bendamustin Hydrochloride (CAS 3543-75-7) Market Research Report 2017 - Research and Markets